

			2013/7/3	
			2013/7/24	
			2013/8/21	
	2013/9/2 No lung metastasis	2013/9/6 Lymph node metastasis 9 × 6 mm (shrunk by 59%)	2013/9/4	
			2013/9/18	

[0062]

[Table 6]

History of therapy and examination of patient having ID No. 22				
Primary focus	Thorax	Abdomen	FOLFOX/Bev	Serum test
G12D	2013/2/1 Lung metastasis in 2 points			
			2013/3/15	2013/3/18 KRAS wild
2012/3/25 Colectomy			2013/3/28	
			2013/4/10	
			2013/4/25	
			2013/5/9	
2013/5/25 Hepatectomy	2013/5/25 Disappearance of lung metastasis		2013/5/23	
			2013/6/5	
			2013/6/20	
			2013/7/3	
			2013/7/17	
			2013/7/31	
			2013/8/14	
			2013/8/28	
			2013/9/11	

5 [0063]

From the circulating DNA of the patient having an ID No. 9 that was obtained before the resection of the primary focus, ultimately the same KRAS gene mutation (G12A) as in the primary focus was observed, while G12A was not detected from the circulating DNA of the same patient that was obtained after the resection of the primary focus. However, G12A was then detected from the serum KRAS, and the tumor recurred after 4 months. That is, in conclusion, the efficacy of bevacizumab was

10